RhumbLine Advisers’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $222K | Sell |
57,566
-1,355
| -2% | -$5.33K | ﹤0.01% | 3068 |
|
|
2025
Q4 | $232K | Sell |
58,921
-11,070
| -16% | -$49K | ﹤0.01% | 3109 |
|
|
2025
Q3 | $327K | Buy |
69,991
+1,704
| +2% | +$6.17K | ﹤0.01% | 2942 |
|
|
2025
Q2 | $212K | Buy |
68,287
+310
| +0.5% | +$1K | ﹤0.01% | 3197 |
|
|
2025
Q1 | $230K | Sell |
67,977
-3,520
| -5% | -$16.4K | ﹤0.01% | 3036 |
|
|
2024
Q4 | $405K | Buy |
71,497
+2,354
| +3% | +$15.2K | ﹤0.01% | 2803 |
|
|
2024
Q3 | $404K | Sell |
69,143
-3,318
| -5% | -$24.1K | ﹤0.01% | 2851 |
|
|
2024
Q2 | $573K | Buy |
72,461
+26,014
| +56% | +$218K | ﹤0.01% | 2573 |
|
|
2024
Q1 | $432K | Buy |
46,447
+3,711
| +9% | +$31.3K | ﹤0.01% | 2755 |
|
|
2023
Q4 | $361K | Sell |
42,736
-304
| -0.7% | -$2.21K | ﹤0.01% | 2860 |
|
|
2023
Q3 | $334K | Buy |
43,040
+1,629
| +4% | +$14.9K | ﹤0.01% | 2870 |
|
|
2023
Q2 | $474K | Buy |
+41,411
| New | +$428K | ﹤0.01% | 2721 |
|
|
2021
Q2 | – | Sell |
-33,868
| Closed | -$160K | – | 3110 |
|
|
2021
Q1 | $160K | Sell |
33,868
-1,300
| -4% | -$8.86K | ﹤0.01% | 2877 |
|
|
2020
Q4 | $251K | Buy |
35,168
+3,100
| +10% | +$29.8K | ﹤0.01% | 2746 |
|
|
2020
Q3 | $342K | Sell |
32,068
-4,945
| -13% | -$58K | ﹤0.01% | 2458 |
|
|
2020
Q2 | $467K | Buy |
37,013
+3,456
| +10% | +$40.2K | ﹤0.01% | 2376 |
|
|
2020
Q1 | $307K | Sell |
33,557
-1,024
| -3% | -$11.8K | ﹤0.01% | 2392 |
|
|
2019
Q4 | $482K | Buy |
34,581
+2,151
| +7% | +$31.3K | ﹤0.01% | 2377 |
|
|
2019
Q3 | $558K | Buy |
32,430
+70
| +0.2% | +$1.47K | ﹤0.01% | 2278 |
|
|
2019
Q2 | $881K | Buy |
32,360
+4,766
| +17% | +$109K | ﹤0.01% | 2111 |
|
|
2019
Q1 | $528K | Sell |
27,594
-395
| -1% | -$5.14K | ﹤0.01% | 2313 |
|
|
2018
Q4 | $263K | Buy |
27,989
+9,086
| +48% | +$117K | ﹤0.01% | 2602 |
|
|
2018
Q3 | $358K | Sell |
18,903
-1,355
| -7% | -$26K | ﹤0.01% | 2425 |
|
|
2018
Q2 | $396K | Buy |
20,258
+3,132
| +18% | +$61.9K | ﹤0.01% | 2409 |
|
|
2018
Q1 | $322K | Buy |
17,126
+2,493
| +17% | +$53.9K | ﹤0.01% | 2399 |
|
|
2017
Q4 | $243K | Sell |
14,633
-1,598
| -10% | -$27.4K | ﹤0.01% | 2550 |
|
|
2017
Q3 | $334K | Buy |
16,231
+140
| +0.9% | +$1.58K | ﹤0.01% | 2509 |
|
|
2017
Q2 | $144K | Buy |
16,091
+4,144
| +35% | +$41.7K | ﹤0.01% | 2847 |
|
|
2017
Q1 | $158K | Buy |
11,947
+499
| +4% | +$6.05K | ﹤0.01% | 2711 |
|
|
2016
Q4 | $146K | Buy |
11,448
+997
| +10% | +$12.8K | ﹤0.01% | 2748 |
|
|
2016
Q3 | $126K | Buy |
+10,451
| New | +$141K | ﹤0.01% | 2781 |
|
Other funds holding VYGR
AC
VPC
VCM
OM
EAM
RhumbLine Advisers's VYGR Position: Q1 2026 in Review
RhumbLine Advisers reduced its Voyager Therapeutics (VYGR) stake by 2.3% in Q1 2026, selling an estimated $5.33K and leaving 57,566 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3068.
RhumbLine Advisers first reported a position in VYGR in Q3 2016 and has held it in 31 quarters since. The position peaked at $881K in Q2 2019. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.
- RhumbLine Advisers held 57,566 shares of Voyager Therapeutics worth $222K as of Q1 2026.
- RhumbLine Advisers sold 1,355 Voyager Therapeutics shares in Q1 2026, an estimated $5.33K.
- Voyager Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3068 holding.
- RhumbLine Advisers first reported a position in Voyager Therapeutics in Q3 2016 and has held it in 31 quarters since.
- RhumbLine Advisers's Voyager Therapeutics position peaked at $881K in Q2 2019.
- 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.